Company · Healthtech & Bio

Histocell

histocell.com ↗ ·Derio ·Series A

Histocell is a Basque biopharmaceutical company and CDMO in regenerative medicine, founded in 2004 as a spin-off of the University of the Basque Country (UPV/EHU) and based at the Bizkaia Science and Technology Park in Derio, near Bilbao. It develops and manufactures advanced therapy medicinal products (adipose-derived mesenchymal stem cell therapies for bone regeneration, spinal cord injury and stress urinary incontinence) alongside a second business unit of medical devices and dermocosmetic products for wound healing, and offers GMP-grade contract manufacturing from its authorised ATMP facility in Larrabetzu. It has raised roughly €9M since 2006 from institutional and private investors, obtained GMP certification in October 2025 for clinical-grade iPSC cell banks with partner REPROCELL, and began clinical trials for stress urinary incontinence in May 2025.

Founded
2004
Founders
3
News
0
Rounds
4
Investors
5
SectorsBiotech, Regenerative Medicine, Cell Therapy, CDMO, Medical Devices, Dermocosmetics Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO

Profile updated 7 Aug 2026

Founders

Begoña Castro Feo
Chief Scientific Officer & Co-founder
Julio Font
CEO & Co-founder
Marta Acilu
Co-founder, Noray Biosciences Group (Histocell parent group); Director of Business Development, Histocell

Global models

No comparables on record yet.

Investors 5

Cell Innovation Partners
www.cell-ip.com ↗
Investor Japan
Investor Spain
Laboratorios Salvat
www.salvat.com ↗
Investor Spain
Investor Japan
Seed Capital Bizkaia
www.seedcapitalbizkaia.eus
Investor Spain

Funding rounds 4

Other · €0.4M
Histocell issued new shares to Japanese stem-cell company ReproCELL Inc. for €0.4M, announced on 7 November 2022 with funding expected 8 Nov…
2022-11-07
Series B · €3M
Histocell closed a €3M capital increase completed in July 2018 and made public around the September 2018 inauguration of its Larrabetzu manu…
2018-09
Series A · €4M
Histocell raised a €4M capital increase that brought in two new shareholders: the Cantabrian pharmaceutical group IFC (Industrial Farmacéuti…
2016-09-29
Seed · €2.5M
Histocell closed a €2.5M capital increase announced on 11 June 2015 to fund the international launch of its Reoxcare wound-healing product, …
2015-06-11

News & media

No coverage on record yet.
Start typing to search across everything.
↑↓ navigate↵ openesc close